sentence1 stringlengths 1.08k 96.5k | sentence2 stringlengths 51 966 | labels stringclasses 3
values | metadata stringlengths 123 2.56k |
|---|---|---|---|
Background:
Emergence agitation (EA) in children is increased after sevoflurane anesthesia. Propofol and dexmedetomidine have been used for prophylactic treatment with controversial results. The aim of the present study was to compare the effect of a single dose of propofol or dexmedetomidine prior to termination of s... | Intervention: dexmedetomidine 0.3 ug/kg-1
Comparator: 10 ml saline 0.9% or propofol 1 mg/kg
Outcome: Modified Children's Hospital of Eastern Ontario Pain Scale (CHEOPS) | -1 | {"evidence_spans": [{"end": 1613, "start": 1483, "text": "roups. The modified Children's Hospital of Eastern Ontario Pain Scale was significantly lower in group D compared to group C and g"}, {"end": 15166, "start": 15070, "text": "ould explain their preventive effect.\r\nThe modified CHEOPS was significantly lower in ... |
Background:
Emergence agitation (EA) in children is increased after sevoflurane anesthesia. Propofol and dexmedetomidine have been used for prophylactic treatment with controversial results. The aim of the present study was to compare the effect of a single dose of propofol or dexmedetomidine prior to termination of s... | Intervention: propofol 1 mg/kg
Comparator: 10 ml saline 0.9% or dexmedetomidine 0.3 ug/kg-1
Outcome: Times to emergence and extubation | 1 | {"evidence_spans": [{"end": 11027, "start": 10924, "text": "erence among the studied groups. Times to emergence and extubation in group P were significantly longer"}], "id": "11967", "pmcid": "3757803", "prompt_id": "11967", "split_group_id": "3757803", "votes": {"1": 2}} |
Background:
Emergence agitation (EA) in children is increased after sevoflurane anesthesia. Propofol and dexmedetomidine have been used for prophylactic treatment with controversial results. The aim of the present study was to compare the effect of a single dose of propofol or dexmedetomidine prior to termination of s... | Intervention: propofol 1 mg/kg or dexmedetomidine 0.3 ug/kg-1
Comparator: 10 ml saline 0.9%
Outcome: Time to discharge from the PACU | 0 | {"evidence_spans": [{"end": 11127, "start": 11028, "text": "compared to group C and group D. Time to discharge from the PACU was not significantly different am"}], "id": "11968", "pmcid": "3757803", "prompt_id": "11968", "split_group_id": "3757803", "votes": {"0": 2}} |
Background
Self-management skills, including medication management, are vital to the health of adolescents and young adults with systemic lupus erythematosus (SLE). The purpose of this study was to assess the feasibility and preliminary effects of an online educational program in a cohort of adolescent and young adult... | Intervention: with a social media (SM) experience
Comparator: without a social media (SM) experience
Outcome: acceptance of illness | 1 | {"evidence_spans": [{"end": 25115, "start": 25056, "text": ".Table 6Empowerment Outcomes (T1) in Control and Social Med"}], "id": "11969", "pmcid": "5852975", "prompt_id": "11969", "split_group_id": "5852975", "votes": {"1": 2}} |
Background
Self-management skills, including medication management, are vital to the health of adolescents and young adults with systemic lupus erythematosus (SLE). The purpose of this study was to assess the feasibility and preliminary effects of an online educational program in a cohort of adolescent and young adult... | Intervention: with a social media (SM) experience
Comparator: without a social media (SM) experience
Outcome: optimism and control over the future | 1 | {"evidence_spans": [{"end": 25259, "start": 25184, "text": "ue*Feeling better informed\r\n3.92\u2009\u00b1\u20090.39\r\n3.96\u00a0\u00b1\u00a00.51\r\n0.85\r\nIncreased confi"}], "id": "11970", "pmcid": "5852975", "prompt_id": "11970", "split_group_id": "5852975", "votes": {"1": 1}} |
Background
Self-management skills, including medication management, are vital to the health of adolescents and young adults with systemic lupus erythematosus (SLE). The purpose of this study was to assess the feasibility and preliminary effects of an online educational program in a cohort of adolescent and young adult... | Intervention: with a social media (SM) experience
Comparator: without a social media (SM) experience
Outcome: social well being | 1 | {"evidence_spans": [{"end": 25368, "start": 25313, "text": ".49\r\n0.11\r\nImproved acceptance of illness\r\n3.15\u2009\u00b1\u20090.51\r"}], "id": "11971", "pmcid": "5852975", "prompt_id": "11971", "split_group_id": "5852975", "votes": {"1": 2}} |
Background
Self-management skills, including medication management, are vital to the health of adolescents and young adults with systemic lupus erythematosus (SLE). The purpose of this study was to assess the feasibility and preliminary effects of an online educational program in a cohort of adolescent and young adult... | Intervention: with a social media (SM) experience
Comparator: without a social media (SM) experience
Outcome: Empowering Outcome Total Score | 1 | {"evidence_spans": [{"end": 24229, "start": 24036, "text": "\r\nAlthough SOA and SOC improved in all subjects (p\u00a0=\u20090.02), the improvement was only statistically significant in the SM group (Table 5). Two of the control subjects did not complete the T1 SOA"}, {"end": 25429, "start": 25371, "text": "65\u00a0\u0... |
Background
Self-management skills, including medication management, are vital to the health of adolescents and young adults with systemic lupus erythematosus (SLE). The purpose of this study was to assess the feasibility and preliminary effects of an online educational program in a cohort of adolescent and young adult... | Intervention: with a social media (SM) experience
Comparator: without a social media (SM) experience
Outcome: CASE Children’s Arthritis Self-Efficacy scale, | 1 | {"evidence_spans": [{"end": 22061, "start": 21989, "text": "Q from T0 to T1 in the group as a whole, but the CASE (p\u00a0=\u20090.05) and SMI"}, {"end": 23190, "start": 23132, "text": "condary Outcomes between Control and Social Media groups i"}], "id": "11973", "pmcid": "5852975", "prompt_id": "11973", "split_group_i... |
Background
Self-management skills, including medication management, are vital to the health of adolescents and young adults with systemic lupus erythematosus (SLE). The purpose of this study was to assess the feasibility and preliminary effects of an online educational program in a cohort of adolescent and young adult... | Intervention: with a social media (SM) experience
Comparator: without a social media (SM) experience
Outcome: SOA sense of agency and SOC sense of community | 1 | {"evidence_spans": [{"end": 1563, "start": 1410, "text": "d not. Secondary outcome measures that improved, only in the SM group, included self-efficacy, sense of agency (SOA), sense of community (SOC), and empow"}, {"end": 23373, "start": 23253, "text": "e*T0 (n\u00a0=\u200912)T1 (n\u00a0=\u200912)p-value*PSQ\r\n0.46\u... |
Background
Self-management skills, including medication management, are vital to the health of adolescents and young adults with systemic lupus erythematosus (SLE). The purpose of this study was to assess the feasibility and preliminary effects of an online educational program in a cohort of adolescent and young adult... | Intervention: with a social media (SM) experience
Comparator: without a social media (SM) experience
Outcome: MASRI medication adherence self-report inventory | 0 | {"evidence_spans": [{"end": 21214, "start": 21127, "text": "1\r\n0.64\u2009\u00b1\u20090.07 (7)\r\n0.76\u2009\u00b1\u20090.07 (7)\r\n0.08\r\n0.72\u2009\u00b1\u20090.05 (11)\r\n0.93\u2009\u00b1\u20090.05 (11)\r\n\r\n<\u20090.00"}, {"end": 21280, "start": 21127, "text": "1\r\n0.64\u2009\u00b1\u20090.07 (7)\r\n0.76\u2009\... |
Background
Self-management skills, including medication management, are vital to the health of adolescents and young adults with systemic lupus erythematosus (SLE). The purpose of this study was to assess the feasibility and preliminary effects of an online educational program in a cohort of adolescent and young adult... | Intervention: with a social media (SM) experience
Comparator: without a social media (SM) experience
Outcome: MPR mediation possession ratio | 1 | {"evidence_spans": [{"end": 20379, "start": 20204, "text": "th regard to race or age.\r\nMPR and MASRI scores before and after the intervention were examined between the control and SM groups (Table\u00a03). The mean MPR significantly improve"}, {"end": 20967, "start": 20875, "text": " scores before and after intervent... |
Background
According to the current guidelines for blood pressure monitoring, clinicians are recommended to measure blood pressure by completely exposing the upper arm. However, it is a common practice that blood pressure is measured with the cuff placed over the sleeve or with the sleeve rolled up. We therefore condu... | Intervention: the sleeve group, the rolled sleeve group,
Comparator: the bare arm group
Outcome: The mean values of systolic blood pressure (SBP) | 0 | {"evidence_spans": [{"end": 1216, "start": 871, "text": "sults\r\nThe mean values of systolic blood pressure (SBP) between the first reading and those of the second reading were 128.5 \u00b1 10.6 mm Hg in the sleeve group, 128.3 \u00b1 10.8 mm Hg in the rolled sleeve group, and 128.3 \u00b1 10.7 mm Hg in the bare arm g... |
Background
According to the current guidelines for blood pressure monitoring, clinicians are recommended to measure blood pressure by completely exposing the upper arm. However, it is a common practice that blood pressure is measured with the cuff placed over the sleeve or with the sleeve rolled up. We therefore condu... | Intervention: the sleeve group, the rolled sleeve group,
Comparator: the bare arm group
Outcome: the mean values of diastolic blood pressure (DBP) | 0 | {"evidence_spans": [{"end": 1570, "start": 1470, "text": "group. These results indicate that there were no significant differences among the three groups (P ="}, {"end": 9729, "start": 9367, "text": "e groups (P = 0.32). In addition, the mean values of diastolic blood pressure (DBP) between measurements of the first re... |
Aim:
For EPs-7630, a herbal drug preparation from Pelargonium sidoides roots, therapeutic effects in respiratory tract infections outside the strict indication for antibiotics have already been demonstrated in adults. Now, a dose-finding study for EPs-7630 was performed in children and adolescents.
Methods:
A tota... | Intervention: 60 mg or 90 mg EPs-7630
Comparator: placebo
Outcome: Bronchitis Severity Score (BSS) | -1 | {"evidence_spans": [{"end": 13688, "start": 13391, "text": "ept for the comparison placebo vs. 30 mg vs. 60 mg EPs 7630 with p = 0.0011, one-sided Bartholomew tests). The subsequent pairwise comparisons of each active treatment group with placebo using the ANCOVA model revealed statistically significant differences in ... |
Aim:
For EPs-7630, a herbal drug preparation from Pelargonium sidoides roots, therapeutic effects in respiratory tract infections outside the strict indication for antibiotics have already been demonstrated in adults. Now, a dose-finding study for EPs-7630 was performed in children and adolescents.
Methods:
A tota... | Intervention: 60 mg or 90 mg EPs-7630
Comparator: placebo
Outcome: ‘coughing’ , ‘sputum’ and ‘pulmonary rales at auscultation’ | -1 | {"evidence_spans": [{"end": 836, "start": 546, "text": "ults:\r\nAfter 7 days of treatment, the change in the BSS total score was significantly better in the 60 mg and 90 mg groups compared with placebo that of the without relevant differences between these two dosages. Especially \u2018coughing\u2019, \u2018sputum\u20... |
Aim:
For EPs-7630, a herbal drug preparation from Pelargonium sidoides roots, therapeutic effects in respiratory tract infections outside the strict indication for antibiotics have already been demonstrated in adults. Now, a dose-finding study for EPs-7630 was performed in children and adolescents.
Methods:
A tota... | Intervention: 30 mg, 60 mg or 90 mg EPs-7630
Comparator: placebo
Outcome: The frequency of AEs | 0 | {"evidence_spans": [{"end": 19153, "start": 19025, "text": "7.2% [20 AEs in 17 patients; EPs 7630 (60 mg) group] and 19.2% [19 AEs in 19 patients; EPs 7630 (90 mg) group] respectively. The"}, {"end": 19449, "start": 19196, "text": "roups was 17.8% (18 AEs in 18 patients), which was similar to that in the placebo. None ... |
Background
Weak transcortical direct current stimulation (tDCS) applied to the cortex can shift the membrane potential of superficial neurons thereby modulating cortical excitability and activity. Here we test the possibility of modifying ongoing activity associated with working memory by tDCS. The concept of working ... | Intervention: anodal and cathodal transcranial direct current (tDCS) stimulation (260 μA) bilaterally at fronto-cortical electrode sites on the scalp over 15 min repeatedly (15 sec-on/15 sec-off)
Comparator: sham-transcortical direct current stimulation (tDCS)
Outcome: reaction time | -1 | {"evidence_spans": [{"end": 1183, "start": 963, "text": "ing. However, reaction time was slowed during both anodal and cathodal stimulation as compared to placebo (p < 0.05) indicating that real stimulation hampered neuronal processing related to response selection and prepara"}], "id": "11991", "pmcid": "1090588", "pr... |
Background
Weak transcortical direct current stimulation (tDCS) applied to the cortex can shift the membrane potential of superficial neurons thereby modulating cortical excitability and activity. Here we test the possibility of modifying ongoing activity associated with working memory by tDCS. The concept of working ... | Intervention: anodal and cathodal transcranial direct current (tDCS) stimulation (260 μA) bilaterally at fronto-cortical electrode sites on the scalp over 15 min repeatedly (15 sec-on/15 sec-off)
Comparator: sham-transcortical direct current stimulation (tDCS)
Outcome: negative and positive response types zero intercep... | 1 | {"evidence_spans": [{"end": 6497, "start": 6344, "text": "ing place [11]. For both negative and positive response types zero intercepts for tDCS were higher (slower reaction times) than for sham-tDCS (F[1,11] = "}, {"end": 6585, "start": 6344, "text": "ing place [11]. For both negative and positive response types zero ... |
AIM
To investigate the efficacy and safety of transcutaneous electroacupuncture (TEA) to alleviate postoperative ileus (POI) after gastrectomy.
METHODS
From April 2014 to February 2017, 63 gastric cancer patients were recruited from the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou... | Intervention: transcutaneous electroacupuncture (TEA)
Comparator: control group
Outcome: Time to first flatus | -1 | {"evidence_spans": [{"end": 964, "start": 829, "text": "SULTS\r\nTime to first flatus in the TEA group was significantly shorter than in the control group (73.19 \u00b1 15.61 vs 82.82 \u00b1 20.25 h, P ="}, {"end": 8913, "start": 8778, "text": "\r\n9/21\r\n0.496\r\nPCIA/PCEA\r\n32/1\r\n29/1\r\n0.833\r\nTEA: Transcutane... |
AIM
To investigate the efficacy and safety of transcutaneous electroacupuncture (TEA) to alleviate postoperative ileus (POI) after gastrectomy.
METHODS
From April 2014 to February 2017, 63 gastric cancer patients were recruited from the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou... | Intervention: transcutaneous electroacupuncture (TEA)
Comparator: control group
Outcome: Time to first flatus after open gastrectomy | -1 | {"evidence_spans": [{"end": 1044, "start": 829, "text": "SULTS\r\nTime to first flatus in the TEA group was significantly shorter than in the control group (73.19 \u00b1 15.61 vs 82.82 \u00b1 20.25 h, P = 0.038), especially for open gastrectomy (76.53 \u00b1 14.29 vs 87.23 \u00b1 20.75 h, P = "}], "id": "11999", "pmcid... |
AIM
To investigate the efficacy and safety of transcutaneous electroacupuncture (TEA) to alleviate postoperative ileus (POI) after gastrectomy.
METHODS
From April 2014 to February 2017, 63 gastric cancer patients were recruited from the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou... | Intervention: transcutaneous electroacupuncture (TEA)
Comparator: control group
Outcome: Bowel sounds on day 2 | 1 | {"evidence_spans": [{"end": 1185, "start": 1045, "text": ".048). Bowel sounds on day 2 in the TEA group were significantly greater than in the control group (2.30 \u00b1 2.61/min vs 1.05 \u00b1 1.26/min, P = "}, {"end": 21431, "start": 21291, "text": ". The secondary outcomes included postoperative symptom assessment a... |
AIM
To investigate the efficacy and safety of transcutaneous electroacupuncture (TEA) to alleviate postoperative ileus (POI) after gastrectomy.
METHODS
From April 2014 to February 2017, 63 gastric cancer patients were recruited from the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou... | Intervention: transcutaneous electroacupuncture (TEA)
Comparator: control group
Outcome: Time to nasogastric tube removal | -1 | {"evidence_spans": [{"end": 1316, "start": 1186, "text": ".017). Time to nasogastric tube removal in the TEA group was earlier than in the control group (4.22 \u00b1 1.01 vs 4.97 \u00b1 1.67 d, P = "}], "id": "12001", "pmcid": "5827033", "prompt_id": "12001", "split_group_id": "5827033", "votes": {"-1": 2}} |
AIM
To investigate the efficacy and safety of transcutaneous electroacupuncture (TEA) to alleviate postoperative ileus (POI) after gastrectomy.
METHODS
From April 2014 to February 2017, 63 gastric cancer patients were recruited from the Second Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou... | Intervention: transcutaneous electroacupuncture (TEA)
Comparator: control group
Outcome: the time to liquid diet | -1 | {"evidence_spans": [{"end": 1393, "start": 1186, "text": ".017). Time to nasogastric tube removal in the TEA group was earlier than in the control group (4.22 \u00b1 1.01 vs 4.97 \u00b1 1.67 d, P = 0.049), as well as the time to liquid diet (5.0 \u00b1 1.34 vs 5.83 \u00b1 2.10 d, P = "}], "id": "12002", "pmcid": "58270... |
Purpose
To investigate the effects of Chamaecyparis obtusa (CO) on human corneal epithelial (HCE) cells, a murine experimental dry eye (EDE) model, and the efficacy of antioxidant eye mask in dry eye disease (DED) patients.
Methods
0.001%, 0.01%, and 0.1% CO extracts were used to treat HCE cells, cell viability... | Intervention: Chamaecyparis obtusa (CO) eye mask 0.1%
Comparator: placebo
Outcome: the DHE intensity | -1 | {"evidence_spans": [{"end": 20936, "start": 20658, "text": "increase in DHE fluorescence was seen after exposure to 200\u2009\u03bcM H2O2. However, pretreatment with CO extracts significantly reduced the DHE intensity in a concentration-dependent manner (0.001% CO: P = 0.96 versus positive control; 0.01% CO: P = 0.04 v... |
Purpose
To investigate the effects of Chamaecyparis obtusa (CO) on human corneal epithelial (HCE) cells, a murine experimental dry eye (EDE) model, and the efficacy of antioxidant eye mask in dry eye disease (DED) patients.
Methods
0.001%, 0.01%, and 0.1% CO extracts were used to treat HCE cells, cell viability... | Intervention: Chamaecyparis obtusa (CO) eye mask 0.1%
Comparator: placebo
Outcome: Tear Volume for murine experimental dry eye (EDE) | 1 | {"evidence_spans": [{"end": 22011, "start": 21898, "text": "0.006\u2009\u03bcL, respectively, in the UT, BSS, 0.001%, 0.01%, and 0.1% CO groups. Tear volume in the 0.1% CO treatment g"}, {"end": 22026, "start": 21898, "text": "0.006\u2009\u03bcL, respectively, in the UT, BSS, 0.001%, 0.01%, and 0.1% CO groups. Tear vol... |
Purpose
To investigate the effects of Chamaecyparis obtusa (CO) on human corneal epithelial (HCE) cells, a murine experimental dry eye (EDE) model, and the efficacy of antioxidant eye mask in dry eye disease (DED) patients.
Methods
0.001%, 0.01%, and 0.1% CO extracts were used to treat HCE cells, cell viability... | Intervention: Chamaecyparis obtusa (CO) eye mask 0.1%
Comparator: placebo
Outcome: Tear Volume | 1 | {"evidence_spans": [{"end": 22026, "start": 21896, "text": "\u00b1\u20090.006\u2009\u03bcL, respectively, in the UT, BSS, 0.001%, 0.01%, and 0.1% CO groups. Tear volume in the 0.1% CO treatment group was signif"}, {"end": 22026, "start": 21898, "text": "0.006\u2009\u03bcL, respectively, in the UT, BSS, 0.001%, 0.01%, a... |
Purpose
To investigate the effects of Chamaecyparis obtusa (CO) on human corneal epithelial (HCE) cells, a murine experimental dry eye (EDE) model, and the efficacy of antioxidant eye mask in dry eye disease (DED) patients.
Methods
0.001%, 0.01%, and 0.1% CO extracts were used to treat HCE cells, cell viability... | Intervention: Chamaecyparis obtusa (CO) eye mask 0.001%
Comparator: balanced salt solution (BSS), experimental dry eye (EDE) model
Outcome: tear film break-up time (TBUT) | 0 | {"evidence_spans": [{"end": 22633, "start": 22475, "text": ")P < 0.01 and P = 0.03, resp.) and BSS (P < 0.01 and P = 0.01, resp.) groups. However, the 0.001% CO extract group did not differ significantly from the EDE a"}, {"end": 22633, "start": 22484, "text": " and P = 0.03, resp.) and BSS (P < 0.01 and P = 0.01, resp... |
Purpose
To investigate the effects of Chamaecyparis obtusa (CO) on human corneal epithelial (HCE) cells, a murine experimental dry eye (EDE) model, and the efficacy of antioxidant eye mask in dry eye disease (DED) patients.
Methods
0.001%, 0.01%, and 0.1% CO extracts were used to treat HCE cells, cell viability... | Intervention: Chamaecyparis obtusa (CO) eye mask 0.1%
Comparator: experimental dry eye (EDE) model
Outcome: The mean concentration of IFN-γ | -1 | {"evidence_spans": [{"end": 23769, "start": 23493, "text": "matory cytokine and chemokine levels in conjunctival tissues are shown in Figure 5. The mean concentration of IFN-\u03b3 was 7.73\u2009\u00b1\u20090.75\u2009pg/mL in the 0.1% CO group. This was significantly lower than the concentrations in the EDE, BSS, and 0... |
Purpose
To investigate the effects of Chamaecyparis obtusa (CO) on human corneal epithelial (HCE) cells, a murine experimental dry eye (EDE) model, and the efficacy of antioxidant eye mask in dry eye disease (DED) patients.
Methods
0.001%, 0.01%, and 0.1% CO extracts were used to treat HCE cells, cell viability... | Intervention: Chamaecyparis obtusa (CO) eye mask 0.1%
Comparator: balanced salt solution (BSS), experimental dry eye (EDE) model
Outcome: The mean levels of IP-10 | -1 | {"evidence_spans": [{"end": 24394, "start": 23956, "text": " = 0.02); however, the levels were not lower than those in any of the other groups.\r\nThe mean levels of IP-10 were 15.66\u2009\u00b1\u20090.51\u2009pg/mL, 15.14\u2009\u00b1\u20091.12\u2009pg/mL, and 13.98\u2009\u00b1\u20090.32\u2009pg/mL in the 0.001%, 0.01%... |
Objective:
The present study was undertaken to determine target organ safety of “Immuforte” to establish relationship between dose or exposure and response and also to identify potential parameters for monitoring adverse effects of “Immuforte” in clinical studies, if any.
Materials and Methods:
A total of 40 males... | Intervention: group II (120 mg/kg BW of Immuforte in gum acacia), group III (360 mg/kg BW of Immuforte in gum acacia)
Comparator: group I (vehicle control; gum acacia)
Outcome: MCV values | 1 | {"evidence_spans": [{"end": 1159, "start": 1052, "text": " 0.05). In females MCV values in low dose and mid dose were significantly higher as compared to control (P "}, {"end": 11529, "start": 11391, "text": " control (P<0.05), values (Mean\u00b1SD), n=10, recovery group n=5\r\nIn females, MCV values in low dose (120 m... |
Objective:
The present study was undertaken to determine target organ safety of “Immuforte” to establish relationship between dose or exposure and response and also to identify potential parameters for monitoring adverse effects of “Immuforte” in clinical studies, if any.
Materials and Methods:
A total of 40 males... | Intervention: group II (120 mg/kg BW of Immuforte in gum acacia), group III (360 mg/kg BW of Immuforte in gum acacia), group IV (600 mg/kg BW of Immuforte in gum acacia)
Comparator: group I (vehicle control; gum acacia)
Outcome: percent lymphocyte count | -1 | {"evidence_spans": [{"end": 11691, "start": 11529, "text": "W) were significantly higher as compared to control (P < 0.05). There was significant decrease in percent lymphocyte count (P < 0.05) and increase in percent neut"}, {"end": 11733, "start": 11530, "text": ") were significantly higher as compared to control (P ... |
Objective:
The present study was undertaken to determine target organ safety of “Immuforte” to establish relationship between dose or exposure and response and also to identify potential parameters for monitoring adverse effects of “Immuforte” in clinical studies, if any.
Materials and Methods:
A total of 40 males... | Intervention: group II (120 mg/kg BW of Immuforte in gum acacia), group III (360 mg/kg BW of Immuforte in gum acacia), group IV (600 mg/kg BW of Immuforte in gum acacia)
Comparator: group I (vehicle control; gum acacia)
Outcome: percent neutrophil count | 1 | {"evidence_spans": [{"end": 1052, "start": 890, "text": "group. The percent neutrophil counts in all the three treated groups of male and female rats were found to be significantly higher than that of control group (P <"}, {"end": 11692, "start": 11530, "text": ") were significantly higher as compared to control (P < 0... |
Introduction
Cyclooxygenase-2 (COX-2) is frequently over-expressed in primary breast cancer. In transgenic breast cancer models, over-expression of COX-2 leads to tumour formation while COX-2 inhibition exerts anti-tumour effects in breast cancer cell lines. To further determine the effect of COX-2 inhibition in prima... | Intervention: pre-operative celecoxib (400 mg) twice daily
Comparator: placebo
Outcome: The Ki-67 mean change | -1 | {"evidence_spans": [{"end": 1863, "start": 1639, "text": "ponse. The Ki-67 mean change relative to baseline was -29.1% (P = 0.019) and -8.2% (P = 0.384) in the treatment and control arm, respectively. Between treatment groups, the change in Ki-67 was statistically significant (P = "}], "id": "12012", "pmcid": "3672758"... |
Introduction
Cyclooxygenase-2 (COX-2) is frequently over-expressed in primary breast cancer. In transgenic breast cancer models, over-expression of COX-2 leads to tumour formation while COX-2 inhibition exerts anti-tumour effects in breast cancer cell lines. To further determine the effect of COX-2 inhibition in prima... | Intervention: pre-operative celecoxib (400 mg) twice daily
Comparator: placebo
Outcome: Cleaved caspase-3 and CD34 expression | 0 | {"evidence_spans": [{"end": 1992, "start": 1864, "text": ".029). Cleaved caspase-3 and CD34 expression were not significantly different between the celecoxib-treated and placebo-treated "}], "id": "12013", "pmcid": "3672758", "prompt_id": "12013", "split_group_id": "3672758", "votes": {"0": 2}} |
Background
This study aimed to study the feasibility, efficacy and safety of using laryngeal mask (LM) ventilation compared with endotracheal intubation (ETI) during neonatal resuscitation.
Methods
Neonates with a heart rate below 60 beats per minute despite 30 s of face mask ventilation were assigned quasi-random... | Intervention: laryngeal mask (LM) ventilation
Comparator: endotracheal intubation (ETI)
Outcome: first attempt at successful insertiontion time | 0 | {"evidence_spans": [{"end": 873, "start": 529, "text": "sults\r\nThere were no significant differences in first attempt at successful insertion (LM, 94.4\u00a0% vs. ETI, 90.6\u00a0%), insertion time (LM, 7.58\u2009\u00b1\u20091.16\u00a0s vs. ETI, 7.89\u2009\u00b1\u20091.52\u00a0s), Apgar score at 1 and 5\u00a0min, resp... |
Background
This study aimed to study the feasibility, efficacy and safety of using laryngeal mask (LM) ventilation compared with endotracheal intubation (ETI) during neonatal resuscitation.
Methods
Neonates with a heart rate below 60 beats per minute despite 30 s of face mask ventilation were assigned quasi-random... | Intervention: laryngeal mask (LM) ventilation
Comparator: endotracheal intubation (ETI)
Outcome: insertion time, Apgar score at 1 and 5min, response time, ventilation time, successful resuscitation | 0 | {"evidence_spans": [{"end": 872, "start": 518, "text": "ared.\r\n\r\nResults\r\nThere were no significant differences in first attempt at successful insertion (LM, 94.4\u00a0% vs. ETI, 90.6\u00a0%), insertion time (LM, 7.58\u2009\u00b1\u20091.16\u00a0s vs. ETI, 7.89\u2009\u00b1\u20091.52\u00a0s), Apgar score at 1 and 5... |
Background
This study aimed to study the feasibility, efficacy and safety of using laryngeal mask (LM) ventilation compared with endotracheal intubation (ETI) during neonatal resuscitation.
Methods
Neonates with a heart rate below 60 beats per minute despite 30 s of face mask ventilation were assigned quasi-random... | Intervention: laryngeal mask (LM) ventilation
Comparator: endotracheal intubation (ETI)
Outcome: Adverse effects | 0 | {"evidence_spans": [{"end": 873, "start": 529, "text": "sults\r\nThere were no significant differences in first attempt at successful insertion (LM, 94.4\u00a0% vs. ETI, 90.6\u00a0%), insertion time (LM, 7.58\u2009\u00b1\u20091.16\u00a0s vs. ETI, 7.89\u2009\u00b1\u20091.52\u00a0s), Apgar score at 1 and 5\u00a0min, resp... |
Objective
Migraines, a common health problem in children and adolescents, still do not have an FDA approved preventive treatment for patients under the age of 18 years. This study compares and contrasts the efficacy and safety of cinnarizine and topiramate in preventing pediatric migraines.
Materials & Methods
In ... | Intervention: cinnarizine
Comparator: topiramate
Outcome: monthly migraine frequency | 0 | {"evidence_spans": [{"end": 14859, "start": 14632, "text": "innarizine: p < 0.001, 95% CI 2.10- 3.90; topiramate: p < 0.001, 95% CI 1.24-3.16). After 8 weeks of treatment compared with the baseline values, reduction of monthly migraine frequency, and intensity demonstrated no statistica"}, {"end": 16152, "start": 16043... |
Objective
Migraines, a common health problem in children and adolescents, still do not have an FDA approved preventive treatment for patients under the age of 18 years. This study compares and contrasts the efficacy and safety of cinnarizine and topiramate in preventing pediatric migraines.
Materials & Methods
In ... | Intervention: cinnarizine
Comparator: topiramate
Outcome: related adverse effects | 0 | {"evidence_spans": [{"end": 18796, "start": 18630, "text": "%) (Table 3). No life-threatening side effects were reported during the double-blind phase in both treatment groups.\r\nThe analysis revealed no statistically significa"}], "id": "12019", "pmcid": "4307364", "prompt_id": "12019", "split_group_id": "4307364", "... |
Background
Although statin therapy is beneficial for the prevention of initial stroke, the benefit for recurrent stroke and its subtypes remains to be determined in Asian, in whom stroke profiles are different from Caucasian. This study examined whether treatment with low-dose pravastatin prevents stroke recurrence in... | Intervention: 10 mg of pravastatin/day
Comparator: no statins
Outcome: the occurrence of stroke and transient ischemic attack (TIA) | 0 | {"evidence_spans": [{"end": 1192, "start": 1116, "text": "though total stroke and TIA similarly occurred in both groups (2.56 vs. 2.65"}, {"end": 14516, "start": 14175, "text": "\u00a0\u00b1\u00a01.45 vs. 4.93\u00a0\u00b1\u00a01.44\u00a0years, respectively).\r\nAs the primary endpoint, total stroke and TIA similarly oc... |
Background
Although statin therapy is beneficial for the prevention of initial stroke, the benefit for recurrent stroke and its subtypes remains to be determined in Asian, in whom stroke profiles are different from Caucasian. This study examined whether treatment with low-dose pravastatin prevents stroke recurrence in... | Intervention: 10mg of pravastatin/day
Comparator: no statins
Outcome: Occurrence of lacunar infarction, cardioembolic infarction, and intracranial hemorrhage, the occurrence of myocardial infarction, vascular accidents, death, and hospitalization | 0 | {"evidence_spans": [{"end": 15158, "start": 14899, "text": "rtain subgroups of patients (Appendix Fig. 2). Occurrence of lacunar infarction (Fig.\u00a03C), cardioembolic infarction (Fig.\u00a03D), and intracranial hemorrhage (Fig.\u00a03E) was similar between the two groups, so was the occurrence of myocardial infarcti... |
Background
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety o... | Intervention: IPE (4g/day)
Comparator: placebo
Outcome: TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-density lipoprotein cholesterol, VLDL-TG, oxidized LDL, and remnant-like par... | -1 | {"evidence_spans": [{"end": 1687, "start": 1227, "text": " groups. Compared with placebo, IPE 4\u00a0g/day significantly reduced TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-den... |
Background
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety o... | Intervention: IPE (4g/day)
Comparator: placebo
Outcome: LDL-C in the total diabetes group total (all subjects with diabetes—overall median baseline glycosylated hemoglobin A1c [A1c] = 6.8%), and less-controlled diabetes (above median baseline A1c) | -1 | {"evidence_spans": [{"end": 1687, "start": 1227, "text": " groups. Compared with placebo, IPE 4\u00a0g/day significantly reduced TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-den... |
Background
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety o... | Intervention: IPE (4g/day)
Comparator: placebo
Outcome: hsCRP in the total (all subjects with diabetes—overall median baseline glycosylated hemoglobin A1c [A1c] = 6.8%), and less-controlled diabetes (above median baseline A1c) | -1 | {"evidence_spans": [{"end": 1687, "start": 1227, "text": " groups. Compared with placebo, IPE 4\u00a0g/day significantly reduced TG, non-high-density lipoprotein cholesterol, very-low-density lipoprotein cholesterol (VLDL-C), lipoprotein-associated phospholipase A2, apolipoprotein B (Apo B), total cholesterol, high-den... |
Background
Icosapent ethyl (IPE) is a high-purity prescription form of eicosapentaenoic acid (EPA) ethyl ester indicated as an adjunct to diet to reduce triglyceride (TG) levels in adult patients with severe (≥500 mg/dL) hypertriglyceridemia. ANCHOR was a 12-week, phase 3 study that evaluated the efficacy and safety o... | Intervention: IPE (4g/day)
Comparator: placebo
Outcome: fasting plasma glucose, A1c, insulin, or homeostasis model assessment-estimated insulin total (all subjects with diabetes—overall median baseline glycosylated hemoglobin A1c [A1c] = 6.8%), better-controlled diabetes (below median baseline A1c), and less-controlled... | 0 | {"evidence_spans": [{"end": 1930, "start": 1779, "text": "betes. There were no significant increases in fasting plasma glucose, A1c, insulin, or homeostasis model assessment-estimated insulin resistance in any"}], "id": "12025", "pmcid": "3718763", "prompt_id": "12025", "split_group_id": "3718763", "votes": {"0": 2}} |
Objectives
To examine whether a mixed lipid emulsion reduces the incidence of parenteral nutrition associated cholestasis (PNAC) in extremely low birth weight (ELBW, <1000 g) infants.
Study design
This double-blind randomized trial of 230 ELBW infants (June 2012-October 2015) was performed at a single level IV neo... | Intervention: mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil-(intervention)
Comparator: soybean oil-based lipid emulsion (control)
Outcome: Parenteral nutrition associated cholestasis | 0 | {"evidence_spans": [{"end": 1205, "start": 1066, "text": "ation). Parenteral nutrition associated cholestasis was 11 of 110 (10.1%) in the intervention and 18 of 113 (15.9%) in the control group (P"}, {"end": 1412, "start": 1067, "text": "tion). Parenteral nutrition associated cholestasis was 11 of 110 (10.1%) in the i... |
Objectives
To examine whether a mixed lipid emulsion reduces the incidence of parenteral nutrition associated cholestasis (PNAC) in extremely low birth weight (ELBW, <1000 g) infants.
Study design
This double-blind randomized trial of 230 ELBW infants (June 2012-October 2015) was performed at a single level IV neo... | Intervention: mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil-(intervention)
Comparator: soybean oil-based lipid emulsion (control)
Outcome: mortality | 0 | {"evidence_spans": [{"end": 14421, "start": 14258, "text": "gated bilirubin, or liver enzymes. Mortality, hospitalization, culture proven sepsis and morbidity (visual, gastrointestinal, neurologic, cardiovascular, and pulmo"}, {"end": 14576, "start": 14422, "text": "ary) did not differ significantly. Infants receiving ... |
Objectives
To examine whether a mixed lipid emulsion reduces the incidence of parenteral nutrition associated cholestasis (PNAC) in extremely low birth weight (ELBW, <1000 g) infants.
Study design
This double-blind randomized trial of 230 ELBW infants (June 2012-October 2015) was performed at a single level IV neo... | Intervention: mixed lipid emulsion composed of soybean oil, medium chain triglycerides, olive oil, and fish oil-(intervention)
Comparator: soybean oil-based lipid emulsion (control)
Outcome: normalization of parenteral nutrition associated cholestasis (PNAC) until discharge | 0 | {"evidence_spans": [{"end": 14682, "start": 14577, "text": "ased lipid emulsion: 1/4; P = .35) or normalization of PNAC until discharge (SMOFLE: 1/3 vs soybean oil-b"}], "id": "12029", "pmcid": "5830079", "prompt_id": "12029", "split_group_id": "5830079", "votes": {"0": 2}} |
Background
Proton-pump inhibitors such as omeprazole are a standard treatment to prevent non-steroidal anti-inflammatory drug-induced upper gastrointestinal mucosal injuries. However, it is unclear which drugs may protect against all NSAID-induced digestive-tract injuries. Here, we compare the efficacy of the gastromu... | Intervention: irsogladine group (Group I; n = 16) receiving diclofenac sodium 75 mg and irsogladine 4 mg daily for 14 days
Comparator: omeprazole group (Group O; n = 16) receiving diclofenac sodium 75 mg and omeprazole 10 mg daily for 14 days
Outcome: change in lesion score in the esophagus, stomach, and duodenum | 0 | {"evidence_spans": [{"end": 1143, "start": 969, "text": "sults\r\nThere was no significant difference between Group I and Group O with respect to the change in lesion score in the esophagus, stomach, and duodenum before and after tre"}, {"end": 14651, "start": 14308, "text": "16 subjects were grade O(no mucosal breaks)... |
Background
Proton-pump inhibitors such as omeprazole are a standard treatment to prevent non-steroidal anti-inflammatory drug-induced upper gastrointestinal mucosal injuries. However, it is unclear which drugs may protect against all NSAID-induced digestive-tract injuries. Here, we compare the efficacy of the gastromu... | Intervention: irsogladine group (Group I; n = 16) receiving diclofenac sodium 75 mg and irsogladine 4 mg daily for 14 days
Comparator: omeprazole group (Group O; n = 16) receiving diclofenac sodium 75 mg and omeprazole 10 mg daily for 14 days
Outcome: the number of small intestinal mucosal breaks | -1 | {"evidence_spans": [{"end": 1579, "start": 1143, "text": "atment.NSAID treatment significantly increased the number of small intestinal mucosal breaks per subject by capsule endoscopic evaluation, from a basal level of 0.1 \u00b1 0.3 up to 1.9 \u00b1 2.0 lesions in Group O (p = 0.0002). In contrast, there were no signi... |
Background
Proton-pump inhibitors such as omeprazole are a standard treatment to prevent non-steroidal anti-inflammatory drug-induced upper gastrointestinal mucosal injuries. However, it is unclear which drugs may protect against all NSAID-induced digestive-tract injuries. Here, we compare the efficacy of the gastromu... | Intervention: irsogladine group (Group I; n = 16) receiving diclofenac sodium 75 mg and irsogladine 4 mg daily for 14 days
Comparator: omeprazole group (Group O; n = 16) receiving diclofenac sodium 75 mg and omeprazole 10 mg daily for 14 days
Outcome: Fecal calprotectin concentration | -1 | {"evidence_spans": [{"end": 1914, "start": 1580, "text": "0040). Fecal calprotectin concentration, when the concentration before treatment was defined as 1, was significantly increased both in Group O (from 1.0 \u00b1 0.0 to 18.1 \u00b1 37.1, p = 0.0002) and Group I (from 1.0 \u00b1 0.0 to 6.0 \u00b1 11.1, p = 0.0280);... |
Background
Proton-pump inhibitors such as omeprazole are a standard treatment to prevent non-steroidal anti-inflammatory drug-induced upper gastrointestinal mucosal injuries. However, it is unclear which drugs may protect against all NSAID-induced digestive-tract injuries. Here, we compare the efficacy of the gastromu... | Intervention: irsogladine group (Group I; n = 16) receiving diclofenac sodium 75 mg and irsogladine 4 mg daily for 14 days
Comparator: omeprazole group (Group O; n = 16) receiving diclofenac sodium 75 mg and omeprazole 10 mg daily for 14 days
Outcome: fecal occult blood levels | -1 | {"evidence_spans": [{"end": 2110, "start": 1914, "text": "<0.05). In addition, fecal occult blood levels increased significantly in Group O (p = 0.0018), but there was no change in Group I (p = 1.0), and the between-group difference was significant (p = "}, {"end": 2111, "start": 1915, "text": "0.05). In addition, feca... |
Background
The protein-calorie malnutrition, resulting in muscle mass loss, frequently occurs in severe COPD patients with chronic respiratory failure (CRF), causing dyspnea, reduced exercise tolerance and impaired quality of life.
The cause of this occurrence is an intake-output energy imbalance. A documented defici... | Intervention: group A with daily dietary supplementation with Creatine 340 mg + 320 mg Coenzyme Q-Ter (Eufortyn®, Scharper Therapeutics Srl) for 2 months
Comparator: Group B received placebo
Outcome: free fat mass index (FFMI) | 1 | {"evidence_spans": [{"end": 1858, "start": 1635, "text": "2 groups. After 2 months of therapy (T1) the FFMI increased in the daily dietary supplementation group (+ 3.7 %) and decreased in the placebo group (- 0.6 %), resulting in a statistically significant (p < 0.001) treatment d"}], "id": "12034", "pmcid": "3707735",... |
Background
The protein-calorie malnutrition, resulting in muscle mass loss, frequently occurs in severe COPD patients with chronic respiratory failure (CRF), causing dyspnea, reduced exercise tolerance and impaired quality of life.
The cause of this occurrence is an intake-output energy imbalance. A documented defici... | Intervention: group A with daily dietary supplementation with Creatine 340 mg + 320 mg Coenzyme Q-Ter (Eufortyn®, Scharper Therapeutics Srl) for 2 months
Comparator: Group B received placebo
Outcome: improvement in the degree of dyspnea, and independence level in activities of daily living; 2) improvement in quality of... | 1 | {"evidence_spans": [{"end": 2320, "start": 1995, "text": "mparison. Group A patients also showed significant: 1) improvement in the degree of dyspnea (VAS: p < 0.05; Borg: p < 0.05; MRC: p < 0.001; BDI1: p < 0.05; BDI3: p < 0.03), and independence level in activities of daily living (p < 0.03); 2) improvement in qualit... |
Background
The protein-calorie malnutrition, resulting in muscle mass loss, frequently occurs in severe COPD patients with chronic respiratory failure (CRF), causing dyspnea, reduced exercise tolerance and impaired quality of life.
The cause of this occurrence is an intake-output energy imbalance. A documented defici... | Intervention: group A with daily dietary supplementation with Creatine 340 mg + 320 mg Coenzyme Q-Ter (Eufortyn®, Scharper Therapeutics Srl) for 2 months
Comparator: Group B received placebo
Outcome: exacerbation number decrease | -1 | {"evidence_spans": [{"end": 2441, "start": 1995, "text": "mparison. Group A patients also showed significant: 1) improvement in the degree of dyspnea (VAS: p < 0.05; Borg: p < 0.05; MRC: p < 0.001; BDI1: p < 0.05; BDI3: p < 0.03), and independence level in activities of daily living (p < 0.03); 2) improvement in qualit... |
Background: Substantial numbers of cancer patients use complementary medicine therapies, even without a supportive evidence base. This study aimed to evaluate in a randomized controlled trial, the use of Medical Qigong (MQ) compared with usual care to improve the quality of life (QOL) of cancer patients.
Patients and ... | Intervention: Medical Qigong (MQ)
Comparator: usual care
Outcome: overall quality of life (QOL), fatigue, mood disturbance, inflammation (CRP) | 1 | {"evidence_spans": [{"end": 983, "start": 680, "text": "s: Regression analysis indicated that the MQ group significantly improved overall QOL (t144\u2009=\u2009\u22125.761, P\u2009<\u20090.001), fatigue (t153\u2009=\u2009\u22125.621, P\u2009<\u20090.001), mood disturbance (t122 =2.346, P\u2009=\u20090.021) and inflamma... |
Objectives
Within a randomized controlled trial contrasting the outcome of manualized cognitive-behavioral (CBT) and short term psychodynamic therapy (PDT) compared to a waiting list condition (the SOPHO-Net trial), we set out to test whether self-reported attachment characteristics change during the treatments and if... | Intervention: cognitive-behavioral (CBT)
Comparator: short term psychodynamic therapy (PDT)
Outcome: Experiences in Close Relationships Questionnaire (ECR-R) | 0 | {"evidence_spans": [{"end": 23124, "start": 22879, "text": "4\r\n.009\r\n6 months follow-up\r\n\r\n\r\nCBT vs. PDT\r\n-.17\r\n.110\r\n12 months follow-up\r\n\r\n\r\nCBT vs.PDT\r\n-.19\r\n.107\r\nCBT = cognitive behavioral therapy, PDT = psychodynamic therapy, WL = waiting list\r\nES = Effect size\r\nWithin WL, the ECR-... |
Background
Web-based interventions present a potentially cost-effective approach to supporting self-management for cancer patients; however, further evidence for acceptability and effectiveness is needed.
Objective
The goal of our research was to assess the effectiveness of an individualized Web-based cognitive be... | Intervention: Web-based cognitive behavioral therapy (CBT) intervention
Comparator: patient education website
Outcome: psychological distress , cancer-specific distress, and unmet psychological care needs | -1 | {"evidence_spans": [{"end": 1402, "start": 1142, "text": "outcomes. However, per-protocol analyses found a greater decrease for the CancerCope group in psychological distress (P=.04), cancer-specific distress (P=.02), and unmet psychological care needs (P=.03) from baseline to 8 weeks compared with the patient educat"}... |
Introduction
Critically ill patients are characterized by increased loss of muscle mass, partially attributed to sepsis and multiple organ failure, as well as immobilization. Recent studies have shown that electrical muscle stimulation (EMS) may be an alternative to active exercise in chronic obstructive pulmonary dis... | Intervention: EMS sessions of both lower extremities (electrical muscle stimulation (EMS)-group)
Comparator: control group
Outcome: Right rectus femoris and right vastus intermedius cross sectional diameter (CSD) | 1 | {"evidence_spans": [{"end": 1743, "start": 974, "text": "sults\r\nTwenty-six patients were finally evaluated. Right rectus femoris and right vastus intermedius CSD decreased in both groups (EMS group: from 1.42 \u00b1 0.48 to 1.31 \u00b1 0.45 cm, P = 0.001 control group: from 1.59 \u00b1 0.53 to 1.37 \u00b1 0.5 cm, P =... |
Introduction
Critically ill patients are characterized by increased loss of muscle mass, partially attributed to sepsis and multiple organ failure, as well as immobilization. Recent studies have shown that electrical muscle stimulation (EMS) may be an alternative to active exercise in chronic obstructive pulmonary dis... | Intervention: EMS sessions of both lower extremities (EMS-group)
Comparator: control group
Outcome: the CSD of the right vastus intermedius | -1 | {"evidence_spans": [{"end": 1742, "start": 1548, "text": "05) and the CSD of the right vastus intermedius decreased significantly less in the EMS group (-0.10 \u00b1 0.05 cm, -12.5 \u00b1 7.4%) as compared to the control group (-0.29 \u00b1 0.28 cm, -21.5 \u00b1 15.3%; P "}], "id": "12042", "pmcid": "2784391", "prompt_... |
Background
Prospective studies in non-Mediterranean populations have consistently related increasing nut consumption to lower coronary heart disease mortality. A small protective effect on all-cause and cancer mortality has also been suggested. To examine the association between frequency of nut consumption and mortal... | Intervention: Mediterranean diets supplemented with nuts or olive oil
Comparator: control diet
Outcome: all-cause mortality | 0 | {"evidence_spans": [{"end": 1273, "start": 1160, "text": "urred. Nut consumption was associated with a significantly reduced risk of all-cause mortality (P for trend <0.05"}], "id": "12043", "pmcid": "3738153", "prompt_id": "12043", "split_group_id": "3738153", "votes": {"0": 1}} |
Aims/hypothesis
The aim of this multicentre, randomised, controlled crossover study was to determine the efficacy of adding continuous glucose monitoring (CGM) to insulin pump therapy (CSII) in type 1 diabetes.
Methods
Children and adults (n = 153) on CSII with HbA1c 7.5–9.5% (58.5–80.3 mmol/mol) were randomised t... | Intervention: continuous glucose monitoring (CGM) Sensor On
Comparator: continuous glucose monitoring (CGM) Sensor Off arm
Outcome: The mean difference in HbA1c | -1 | {"evidence_spans": [{"end": 1075, "start": 878, "text": "lysis. The mean difference in HbA1c was \u20130.43% (\u20134.74\u00a0mmol/mol) in favour of the Sensor On arm (8.04% [64.34\u00a0mmol/mol] vs 8.47% [69.08\u00a0mmol/mol]; 95% CI \u22120.32%, \u22120.55% [\u22123.50, \u22126.01\u00a0mmol/mol]; p\u2009<\u2009"}], "... |
Aims/hypothesis
The aim of this multicentre, randomised, controlled crossover study was to determine the efficacy of adding continuous glucose monitoring (CGM) to insulin pump therapy (CSII) in type 1 diabetes.
Methods
Children and adults (n = 153) on CSII with HbA1c 7.5–9.5% (58.5–80.3 mmol/mol) were randomised t... | Intervention: continuous glucose monitoring (CGM) Sensor On
Comparator: continuous glucose monitoring (CGM) Sensor Off arm
Outcome: time was spent with sensor glucose | -1 | {"evidence_spans": [{"end": 1285, "start": 1076, "text": ".001). Following cessation of glucose sensing, HbA1c reverted to baseline levels. Less time was spent with sensor glucose <3.9\u00a0mmol/l during the Sensor On arm than in the Sensor Off arm (19 vs 31\u00a0min/day; p\u2009=\u2009"}, {"end": 15699, "start": 15329... |
Aims/hypothesis
The aim of this multicentre, randomised, controlled crossover study was to determine the efficacy of adding continuous glucose monitoring (CGM) to insulin pump therapy (CSII) in type 1 diabetes.
Methods
Children and adults (n = 153) on CSII with HbA1c 7.5–9.5% (58.5–80.3 mmol/mol) were randomised t... | Intervention: continuous glucose monitoring (CGM) Sensor On
Comparator: continuous glucose monitoring (CGM) Sensor Off arm
Outcome: The mean number of daily boluses | 1 | {"evidence_spans": [{"end": 1386, "start": 1286, "text": ".009). The mean number of daily boluses increased in the Sensor On arm (6.8\u2009\u00b1\u20092.5 vs 5.8\u2009\u00b1\u20091.9, p\u2009<\u2009"}], "id": "12047", "pmcid": "3483098", "prompt_id": "12047", "split_group_id": "3483098", "votes": {"1": 2}} |
Aims/hypothesis
The aim of this multicentre, randomised, controlled crossover study was to determine the efficacy of adding continuous glucose monitoring (CGM) to insulin pump therapy (CSII) in type 1 diabetes.
Methods
Children and adults (n = 153) on CSII with HbA1c 7.5–9.5% (58.5–80.3 mmol/mol) were randomised t... | Intervention: continuous glucose monitoring (CGM) Sensor On
Comparator: continuous glucose monitoring (CGM) Sensor Off arm
Outcome: the frequency of use of the temporary basal rate and manual insulin suspend functions | 1 | {"evidence_spans": [{"end": 19187, "start": 18837, "text": "e daily total insulin dose (49.0\u2009\u00b1\u200923.4 vs 47.4\u2009\u00b1\u200922.3 U) or relative proportion of bolus insulin (52.8\u2009\u00b1\u200910.6% vs 52.5\u2009\u00b1\u200911.0%) were not significantly different between the two study periods. In addi... |
Aims/hypothesis
The aim of this multicentre, randomised, controlled crossover study was to determine the efficacy of adding continuous glucose monitoring (CGM) to insulin pump therapy (CSII) in type 1 diabetes.
Methods
Children and adults (n = 153) on CSII with HbA1c 7.5–9.5% (58.5–80.3 mmol/mol) were randomised t... | Intervention: continuous glucose monitoring (CGM) Sensor On
Comparator: continuous glucose monitoring (CGM) Sensor Off arm
Outcome: events of severe hypoglycaemia | 0 | {"evidence_spans": [{"end": 1683, "start": 1570, "text": "tions. Four vs two events of severe hypoglycaemia occurred in the Sensor On and Sensor Off arm, respectively (p\u2009="}], "id": "12049", "pmcid": "3483098", "prompt_id": "12049", "split_group_id": "3483098", "votes": {"0": 2}} |
Objective
In practical guidelines for management of allergic rhinitis in Japan, pranlukast is a leukotriene receptor antagonist recommended for the treatment of pollinosis. However, the effect of pranlukast on nasal symptoms for cedar pollinosis has not been thoroughly investigated. The aim of this study is to examine... | Intervention: pranlukast
Comparator: placebo
Outcome: Sneezing | 0 | {"evidence_spans": [{"end": 9874, "start": 9526, "text": "T: capsulated hydrophilic carrier polymer radioallergosorbent test.\r\n\r\nNasal symptom scores\r\nSneezing: During exposure in the pollen challenge chamber, the sneezing score was \u22640.5 in both the pranlukast and placebo groups, indicating mild symptoms and... |
Objective
In practical guidelines for management of allergic rhinitis in Japan, pranlukast is a leukotriene receptor antagonist recommended for the treatment of pollinosis. However, the effect of pranlukast on nasal symptoms for cedar pollinosis has not been thoroughly investigated. The aim of this study is to examine... | Intervention: pranlukast
Comparator: placebo
Outcome: nasal discharge score | -1 | {"evidence_spans": [{"end": 11070, "start": 10854, "text": "=\u20090.020), 90\u2009minutes (1.051\u2009vs. 0.564, p\u2009=\u20090.036), and 180\u2009minutes (1.128\u2009vs. 0.692, p\u2009=\u20090.053). After the subjects left the chamber, the score increased continuously until the following morning in the placebo group... |
Objective
In practical guidelines for management of allergic rhinitis in Japan, pranlukast is a leukotriene receptor antagonist recommended for the treatment of pollinosis. However, the effect of pranlukast on nasal symptoms for cedar pollinosis has not been thoroughly investigated. The aim of this study is to examine... | Intervention: pranlukast
Comparator: placebo
Outcome: Nasal itching | 0 | {"evidence_spans": [{"end": 11299, "start": 11116, "text": "kast group (1.179\u2009vs. 0.718, p\u2009=\u20090.037) (Figure 4).\r\nFigure 4.\u2002Changes in nasal congestion score.\r\nNasal itching: During exposure in the pollen challenge chamber, the nasal itching sc"}], "id": "12052", "pmcid": "4980729", "prompt_id": ... |
Objective
In practical guidelines for management of allergic rhinitis in Japan, pranlukast is a leukotriene receptor antagonist recommended for the treatment of pollinosis. However, the effect of pranlukast on nasal symptoms for cedar pollinosis has not been thoroughly investigated. The aim of this study is to examine... | Intervention: pranlukast
Comparator: placebo
Outcome: Itchy eyes | -1 | {"evidence_spans": [{"end": 12711, "start": 12274, "text": ", p\u2009=\u20090.038) (Figure 5).\r\nFigure 5.\u2002Changes in total nasal symptom score.\r\n\r\nTotal eye symptoms scores\r\nItchy eyes: During exposure in the pollen challenge chamber, score for itchy eyes increased slightly to about 0.5 and 0.3 in the plac... |
Objective
In practical guidelines for management of allergic rhinitis in Japan, pranlukast is a leukotriene receptor antagonist recommended for the treatment of pollinosis. However, the effect of pranlukast on nasal symptoms for cedar pollinosis has not been thoroughly investigated. The aim of this study is to examine... | Intervention: pranlukast
Comparator: placebo
Outcome: Watery eyes | 0 | {"evidence_spans": [{"end": 12884, "start": 12712, "text": "n the following afternoon in the pranlukast compared to the placebo group (0.154\u2009vs. 0.436, p\u2009=\u20090.039).\r\nWatery eyes: During and after exposure in the pollen challenge cham"}, {"end": 12884, "start": 12725, "text": "ng afternoon in the pranluk... |
Background
Venous leg ulcers, affecting approximately 1% of the population, are costly to manage due to poor healing and high recurrence rates. We evaluated an evidence-informed leg ulcer care protocol with two frequently used high compression systems: ‘four-layer bandage’ (4LB) and ‘short-stretch bandage’ (SSB).
M... | Intervention: four-layer bandage (4LB)
Comparator: short-stretch bandage (SSB).
Outcome: Healing rates of ulcers | 0 | {"evidence_spans": [{"end": 18191, "start": 17974, "text": "with SSB, resulting in an average 15 ulcer-free days gained with 4LB; however, the 95% confidence interval (\u221232 days, 21 days) crossed zero, indicating no statistically significant difference between treatment groups."}, {"end": 18192, "start": 17975, "te... |
Background
Venous leg ulcers, affecting approximately 1% of the population, are costly to manage due to poor healing and high recurrence rates. We evaluated an evidence-informed leg ulcer care protocol with two frequently used high compression systems: ‘four-layer bandage’ (4LB) and ‘short-stretch bandage’ (SSB).
M... | Intervention: four-layer bandage (4LB)
Comparator: short-stretch bandage (SSB).
Outcome: recurrence rates of ulcers | 0 | {"evidence_spans": [{"end": 19147, "start": 18872, "text": "ed from the 1000 bootstrapped samples. QALY: Quality-adjusted life year.\r\nThe mean quality-of-life weights were comparable for both groups at regular assessment intervals while participants were on treatment (Figure 1, solid lines). Both groups attained simi... |
Rationale
3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally and investigated as an adjunct to psychotherapy. Methylphenidate and modafinil are psychostimulants that are used to treat attention-deficit/hyperactivity disorder and narcolepsy, respectively, but they are also misused as cognitive enhancers. L... | Intervention: 3,4-Methylenedioxymethamphetamine (MDMA)
Comparator: placebo or methylphenidate or modafinil
Outcome: the recognition of fearful faces | -1 | {"evidence_spans": [{"end": 26431, "start": 26251, "text": "ocrine effects. The data are expressed as the mean\u00a0\u00b1\u00a0SEM in 24 subjects. The substances were administered at t\u00a0=\u00a00\r\n\r\n\r\n\r\nFacial emotion recognition\r\nThe effects of MDMA, methylphe"}, {"end": 26432, "start": 26252, "text": "c... |
Rationale
3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally and investigated as an adjunct to psychotherapy. Methylphenidate and modafinil are psychostimulants that are used to treat attention-deficit/hyperactivity disorder and narcolepsy, respectively, but they are also misused as cognitive enhancers. L... | Intervention: 3,4-Methylenedioxymethamphetamine (MDMA)
Comparator: placebo
Outcome: scores on the “Evaluative” “Physiological” and “Motivational” scales | 1 | {"evidence_spans": [{"end": 27396, "start": 27248, "text": ".05). However, methylphenidate and modafinil did not alter emotion recognition accuracy for any of the emotions.Fig. 5On the Facial Emotion Recognit"}, {"end": 27397, "start": 27249, "text": "05). However, methylphenidate and modafinil did not alter emotion re... |
Rationale
3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally and investigated as an adjunct to psychotherapy. Methylphenidate and modafinil are psychostimulants that are used to treat attention-deficit/hyperactivity disorder and narcolepsy, respectively, but they are also misused as cognitive enhancers. L... | Intervention: 3,4-Methylenedioxymethamphetamine (MDMA)
Comparator: placebo
Outcome: misclassification of emotions as happy | 1 | {"evidence_spans": [{"end": 26650, "start": 26433, "text": "date, and modafinil on the FERT are shown in Fig. 5. Complete datasets were unavailable for two subjects because of technical reasons. The ANOVA revealed a significant main effect of drug on the decoding accuracy of f"}, {"end": 26650, "start": 26545, "text": ... |
Rationale
3,4-Methylenedioxymethamphetamine (MDMA) is used recreationally and investigated as an adjunct to psychotherapy. Methylphenidate and modafinil are psychostimulants that are used to treat attention-deficit/hyperactivity disorder and narcolepsy, respectively, but they are also misused as cognitive enhancers. L... | Intervention: 3,4-Methylenedioxymethamphetamine (MDMA) or methylphenidate or modafinil
Comparator: placebo
Outcome: Adverse effects | 1 | {"evidence_spans": [{"end": 28748, "start": 28567, "text": "r methylphenidate, modafinil, MDMA, MDA, and HMMA are shown in Supplementary Fig. S2. The C\r\nmax values for MDMA, MDA, and HMMA were 192\u00a0\u00b1\u00a08.7, 9.1\u00a0\u00b1\u00a00.4, and 69.1\u00a0\u00b1\u00a010.0\u00a0ng/ml, res"}, {"end": 28722, "start":... |
Background and Objective:
A prospective randomized control study was conducted to compare and evaluate quality of anesthesia with ketamine or fentanyl as co-induction with propofol.
Materials and Methods:
Sixty ASA I or II, 18–50 year old patients who were scheduled for minor surgeries of short duration (<30 min a... | Intervention: ketamine injection 0.5 mg/kg (group I)
Comparator: fentanyl injection (1.5 μg/kg) (group II)
Outcome: incidence of apnoea | -1 | {"evidence_spans": [{"end": 6215, "start": 6166, "text": "5) in both the groups while incidence of apnoea w"}, {"end": 6217, "start": 6167, "text": ") in both the groups while incidence of apnoea was"}], "id": "12062", "pmcid": "3354371", "prompt_id": "12062", "split_group_id": "3354371", "votes": {"-1": 2}} |
Background and Objective:
A prospective randomized control study was conducted to compare and evaluate quality of anesthesia with ketamine or fentanyl as co-induction with propofol.
Materials and Methods:
Sixty ASA I or II, 18–50 year old patients who were scheduled for minor surgeries of short duration (<30 min a... | Intervention: ketamine injection 0.5 mg/kg
Comparator: fentanyl injection (1.5 μg/kg)
Outcome: Awakening time (spontaneous eye opening) and recovery time (when patient was able to answer simple questions such as name, age, date of birth, time, and place) | 0 | {"evidence_spans": [{"end": 6560, "start": 6342, "text": "raoperative adverse effects\r\nAwakening time (spontaneous eye opening) and recovery time (when patient was able to answer simple questions such as name, age, date of birth, time, and place) were statistically insignific"}], "id": "12063", "pmcid": "3354371", "p... |
Background and Objective:
A prospective randomized control study was conducted to compare and evaluate quality of anesthesia with ketamine or fentanyl as co-induction with propofol.
Materials and Methods:
Sixty ASA I or II, 18–50 year old patients who were scheduled for minor surgeries of short duration (<30 min a... | Intervention: ketamine injection 0.5 mg/kg
Comparator: fentanyl injection (1.5 μg/kg)
Outcome: Pain due to propofol injection and presence of abnormal movements | 0 | {"evidence_spans": [{"end": 6160, "start": 6034, "text": "Table 2Types of surgeries\r\nPain due to propofol injection and presence of abnormal movements were statistically insignificant "}], "id": "12065", "pmcid": "3354371", "prompt_id": "12065", "split_group_id": "3354371", "votes": {"0": 2}} |
Background:
To determine whether the phosphodiesterase type 5 inhibitor, Sildenafil citrate, affects uteroplacental perfusion.
Materials and Methods:
Based on a randomized double-blinded and placebo-controlled trial, forty one pregnant women with documented intrauterine growth retardation at 24-37 weeks of gestati... | Intervention: Sildenafil
Comparator: placebo
Outcome: Mean Middle Cerebral Artery Pulsatility Index (MCA PI) | 1 | {"evidence_spans": [{"end": 1024, "start": 671, "text": "ults:\r\nSildenafil group fetuses demonstrated a significant decrease in systolic/diastolic ratios (0.60 [SD 0.40] [95% Cl 0.37-0.84], P=0.000), and pulsatility index (0.12 [SD 0.15] [95% Cl 0.02-0.22], P=0.019) for the umbilical artery and a significant increase... |
Background:
To determine whether the phosphodiesterase type 5 inhibitor, Sildenafil citrate, affects uteroplacental perfusion.
Materials and Methods:
Based on a randomized double-blinded and placebo-controlled trial, forty one pregnant women with documented intrauterine growth retardation at 24-37 weeks of gestati... | Intervention: Sildenafil
Comparator: placebo
Outcome: Mean umbilical artery systolic/diastolic ratio (UA S/D) | -1 | {"evidence_spans": [{"end": 898, "start": 671, "text": "ults:\r\nSildenafil group fetuses demonstrated a significant decrease in systolic/diastolic ratios (0.60 [SD 0.40] [95% Cl 0.37-0.84], P=0.000), and pulsatility index (0.12 [SD 0.15] [95% Cl 0.02-0.22], P=0.019) for the umbilical"}, {"end": 11111, "start": 10925, ... |
Background:
To determine whether the phosphodiesterase type 5 inhibitor, Sildenafil citrate, affects uteroplacental perfusion.
Materials and Methods:
Based on a randomized double-blinded and placebo-controlled trial, forty one pregnant women with documented intrauterine growth retardation at 24-37 weeks of gestati... | Intervention: Sildenafil
Comparator: placebo
Outcome: Mean umbilical artery pulsatility index (UA PI) | -1 | {"evidence_spans": [{"end": 898, "start": 671, "text": "ults:\r\nSildenafil group fetuses demonstrated a significant decrease in systolic/diastolic ratios (0.60 [SD 0.40] [95% Cl 0.37-0.84], P=0.000), and pulsatility index (0.12 [SD 0.15] [95% Cl 0.02-0.22], P=0.019) for the umbilical"}, {"end": 11289, "start": 11112, ... |
Background:
Athletes use flavonoids as antioxidant to enhance endurance and physical performance. In vitro data indicate flavonoids have antioxidative and antiinflammatory functions but data in human studies are limited. The aim of this study was to determine the effects of a 2-month flavonoid quercetin supplementatio... | Intervention: 500 mg quercetin + 250 mg vitamin C as pro-oxidant (Q+C),
Comparator: 250 mg of vitamin C alone (C), and placebo (Control), 500 mg of quercetin alone (Q)
Outcome: interleukin 6 and F2-isoprostane | 0 | {"evidence_spans": [{"end": 7585, "start": 7472, "text": "1 while for group 3 at P<0.1. Within group differences in interleukin 6 and F2-isoprostane only for group 1 was m"}, {"end": 7586, "start": 7473, "text": " while for group 3 at P<0.1. Within group differences in interleukin 6 and F2-isoprostane only for group 1 ... |
Background:
Athletes use flavonoids as antioxidant to enhance endurance and physical performance. In vitro data indicate flavonoids have antioxidative and antiinflammatory functions but data in human studies are limited. The aim of this study was to determine the effects of a 2-month flavonoid quercetin supplementatio... | Intervention: 500 mg quercetin + 250 mg vitamin C as pro-oxidant (Q+C),
Comparator: 250 mg of vitamin C alone (C), and placebo (Control), 500 mg of quercetin alone (Q)
Outcome: E-selectin | 0 | {"evidence_spans": [{"end": 7684, "start": 7587, "text": "ginally significant (P<0.1). Also, pre- and postchanges in E-selectin was marginally significant "}, {"end": 8123, "start": 8023, "text": "th the control group (P<0.1). There were no differences in E-selectin between active treatment group"}], "id": "12075", "pm... |
Background and Aim:
Therapeutic use of nonopioid analgesic such as paracetamol (PCM) is an alternative to opioids, so to avoid the established side effects associated with opioids, PCM is commonly used due to its analgesic and antipyretic effects. Recently, dexmedetomidine has also emerged on the anesthesia front with... | Intervention: 1 g intravenous PCM, in 100 ml solution before incision (Group I)
Comparator: dexmedetomidine 1 μg/kg as bolus over 10 min followed by infusion of 0.5 μg/kg/h (Group II)
Outcome: Postoperative analgesic requirement | -1 | {"evidence_spans": [{"end": 1622, "start": 1424, "text": "ults:\r\nPostoperative analgesic requirement significantly decreased (P = 0.001), with a lower score on VAS, better patient satisfaction scores, and Ramsay Sedation Score ranges from 3 to 5 (62%) in G"}], "id": "12077", "pmcid": "5752804", "prompt_id": "12077", ... |
Background and Aim:
Therapeutic use of nonopioid analgesic such as paracetamol (PCM) is an alternative to opioids, so to avoid the established side effects associated with opioids, PCM is commonly used due to its analgesic and antipyretic effects. Recently, dexmedetomidine has also emerged on the anesthesia front with... | Intervention: 1 g intravenous PCM, in 100 ml solution before incision (Group I)
Comparator: dexmedetomidine 1 μg/kg as bolus over 10 min followed by infusion of 0.5 μg/kg/h (Group II)
Outcome: nausea and vomiting, hypotension, and bradycardia | 0 | {"evidence_spans": [{"end": 10990, "start": 10749, "text": " group [Figure 3]. The comparative incidence of nausea and vomiting and other side effects such as hypotension and bradycardia was not significant statistically except for the incidence of shivering in dexmedetomidine group (2%) as compared "}], "id": "12078",... |
Background and Aims:
Hyponatraemia is frequent in post-operative patients and may be corrected with hypertonic saline (HTS). Oral tolvaptan is used to treat hypervolaemic or euvolaemic hyponatraemia. This study was performed to assess the efficacy of oral tolvaptan in correcting postoperative hyponatraemia compared to... | Intervention: Group H (n = 20), 3% HTS was infused at 20–30 mL/h aiming for correction of 6 mEq/L/day
Comparator: Group T received oral tolvaptan 15 mg on the 1st day. If daily correction was <4 mEq/L, the dose was increased by 15 mg/day to a maximum of 45 mg
Outcome: sodium levels | -1 | {"evidence_spans": [{"end": 1035, "start": 920, "text": "roups. At 72 h, Group T had significantly higher sodium levels as compared to Group H (133.4 \u00b1 1.9 vs. 131.3 \u00b1 2.4 "}, {"end": 1034, "start": 928, "text": "t 72 h, Group T had significantly higher sodium levels as compared to Group H (133.4 \u00b1 1.9 v... |
Objective
Many patients with late-diagnosed phenylketonuria (PKU) suffer from severe behavior problems. This study compares the effects of buspirone and risperidone on reducing behavior disorders in these patients.
Materials & Methods
In this crossover clinical trial study, patients with severe behavior disorders ... | Intervention: risperidone
Comparator: buspirone
Outcome: mean serum phenylalanine | 0 | {"evidence_spans": [{"end": 10948, "start": 10742, "text": "he patients had malignant PKU. \r\nNone of the patients had phenylalanine more than 10 mg/ dl during treatment, and the mean serum phenylalanine of the patients was not significantly different during treatmen"}], "id": "12087", "pmcid": "4307366", "prompt_id":... |
Objective
Many patients with late-diagnosed phenylketonuria (PKU) suffer from severe behavior problems. This study compares the effects of buspirone and risperidone on reducing behavior disorders in these patients.
Materials & Methods
In this crossover clinical trial study, patients with severe behavior disorders ... | Intervention: risperidone
Comparator: buspirone
Outcome: hyperactivity and disruptive/stereotypic | -1 | {"evidence_spans": [{"end": 1105, "start": 971, "text": "sorder. Risperidone was significantly effective in reducing the NCBRF subscales of hyperactivity disruptive/stereotypic, and conduct p"}, {"end": 11764, "start": 11535, "text": "significant differences (Table 2). \r\nIn comparison of the effects of risperidone an... |
Objective
Many patients with late-diagnosed phenylketonuria (PKU) suffer from severe behavior problems. This study compares the effects of buspirone and risperidone on reducing behavior disorders in these patients.
Materials & Methods
In this crossover clinical trial study, patients with severe behavior disorders ... | Intervention: risperidone
Comparator: buspirone
Outcome: self-isolation and insecure/anxious | -1 | {"evidence_spans": [{"end": 11932, "start": 11771, "text": "rent from the buspirone group. Also, a decrease in the subscales of self-isolation (p=0.004) and insecure/anxious (p=0.031) in risperidone group was significantl"}], "id": "12089", "pmcid": "4307366", "prompt_id": "12089", "split_group_id": "4307366", "votes":... |
Background:
Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD).
Objective/methods:
We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed or AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg... | Intervention: AZL-M/CTD 20/12.5 mg once daily or AZL-M/CTD 40/12.5 mg once daily
Comparator: olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily
Outcome: systolic blood pressure (SBP) | -1 | {"evidence_spans": [{"end": 1032, "start": 816, "text": "ults:\r\nGreater reductions in clinic SBP from a baseline of 165\u200ammHg were observed (P\u200a<\u200a0.001) in both AZL-M/CTD arms (\u221237.6 and \u221238.2\u200ammHg) versus OLM/HCTZ (\u221231.5\u200ammHg), despite greater dose titration in the OLM/HCTZ"}, {... |
Background:
Azilsartan medoxomil (AZL-M), an angiotensin II receptor blocker, has been developed in fixed-dose combinations (FDCs) with chlorthalidone (CTD).
Objective/methods:
We compared FDCs of AZL-M/CTD 20/12.5 mg once daily titrated to 40/25 mg if needed or AZL-M/CTD 40/12.5 mg once daily titrated to 80/25 mg... | Intervention: AZL-M/CTD 20/12.5 mg once daily or AZL-M/CTD 40/12.5 mg once daily
Comparator: olmesartan medoxomil (OLM)-hydrochlorothiazide (HCTZ) 20/12.5 mg FDC once daily
Outcome: systolic blood pressure (SBP) at week 8 | -1 | {"evidence_spans": [{"end": 1152, "start": 1033, "text": "group. At 8 weeks, both AZL-M/CTD FDCs reduced 24-h SBP more than OLM/HCTZ (\u221226.4 and \u221227.9 versus \u221220.7\u200ammHg; both P\u200a<"}, {"end": 1153, "start": 1033, "text": "group. At 8 weeks, both AZL-M/CTD FDCs reduced 24-h SBP more than OLM/HCTZ (... |
Background
Patient reported outcomes (PROs) are especially useful in assessing treatments for rheumatoid arthritis (RA) since they measure dimensions of health-related quality of life that cannot be captured using strictly objective physiological measures. The aim of this study was to compare the effects of combinatio... | Intervention: etanercept and methotrexate (ETN + MTX)
Comparator: synthetic disease modifying antirheumatic drugs (DMARDs) and methotrexate (DMARD + MTX)
Outcome: physical and mental component summaries | 1 | {"evidence_spans": [{"end": 1607, "start": 1451, "text": " SF-36 Summary Scores for physical and mental components and for 6 of 8 health domains showed significantly greater improvements at week16 for the ETN\u2009+\u2009MTX"}, {"end": 13878, "start": 13699, "text": "t summary scores were improved by 7.3 points (17.5%)... |
Background
Patient reported outcomes (PROs) are especially useful in assessing treatments for rheumatoid arthritis (RA) since they measure dimensions of health-related quality of life that cannot be captured using strictly objective physiological measures. The aim of this study was to compare the effects of combinatio... | Intervention: etanercept and methotrexate (ETN + MTX)
Comparator: synthetic disease modifying antirheumatic drugs (DMARDs) and methotrexate (DMARD + MTX)
Outcome: improvement in the FACIT-Fatigue scale | 1 | {"evidence_spans": [{"end": 13878, "start": 13699, "text": "t summary scores were improved by 7.3 points (17.5%) and 5.4 points (13.3%), respectively. The improvements were significantly greater among the ETN\u2009+\u2009MTX patients compared to DMA"}, {"end": 15297, "start": 15099, "text": "roups reported similar fati... |
Background
Patient reported outcomes (PROs) are especially useful in assessing treatments for rheumatoid arthritis (RA) since they measure dimensions of health-related quality of life that cannot be captured using strictly objective physiological measures. The aim of this study was to compare the effects of combinatio... | Intervention: etanercept and methotrexate (ETN + MTX)
Comparator: synthetic disease modifying antirheumatic drugs (DMARDs) and methotrexate (DMARD + MTX)
Outcome: activity impairment of The Work Productivity and Activity Impairment Questionnaire | -1 | {"evidence_spans": [{"end": 16960, "start": 16742, "text": "e\u00a03). Both groups reported similar percent usual activity impairment (approximately 59%) due to health at baseline (Table\u00a03; P\u2009=\u20090.983). At week 16, percent usual activity impairment due to health declined to 41% in th"}, {"end": 24096, "st... |
Introduction
Epidemiologic evidence suggests that tomato-based products could reduce the risk of cardiovascular diseases. One of the main cardiovascular risk factors is low levels of high-density lipoprotein cholesterol (HDL-C). This study aimed to prospectively evaluate the effect of tomato consumption on HDL-C level... | Intervention: two uncooked Roma tomatoes a day
Comparator: 300 g of cucumber (control group)
Outcome: triglycerides, LDL-C, and total cholesterol | 0 | {"evidence_spans": [{"end": 14879, "start": 14796, "text": "HDL-C was 5.0 \u00b1 2.8 mg/dL (range 1\u201312 mg/dL). Levels of triglycerides, LDL-C, and t"}, {"end": 14880, "start": 14797, "text": "DL-C was 5.0 \u00b1 2.8 mg/dL (range 1\u201312 mg/dL). Levels of triglycerides, LDL-C, and to"}], "id": "12098", "pmcid": "... |
Background
Diagnostic error and delay are critical impediments to the safety of critically ill patients. Checklist for early recognition and treatment of acute illness and injury (CERTAIN) has been developed as a tool that facilitates timely and error-free evaluation of critically ill patients. While the focused histo... | Intervention: choreography of the focused history in series
Comparator: in parallel to the clinical assessment of an acutely decompensating patient
Outcome: The median (IQR) time to completion of the tasks | 0 | {"evidence_spans": [{"end": 1933, "start": 1796, "text": "\u20090.57. The median (IQR) time to completion of the tasks in series was 125 (112 \u2013 158) seconds and in parallel 122 (108 \u2013 158) seconds, p\u2009"}, {"end": 14963, "start": 14795, "text": " p\u2009=\u20090.57 (Additional file 1: Figure S1). Secondari... |
Background
Diagnostic error and delay are critical impediments to the safety of critically ill patients. Checklist for early recognition and treatment of acute illness and injury (CERTAIN) has been developed as a tool that facilitates timely and error-free evaluation of critically ill patients. While the focused histo... | Intervention: choreography of the focused history in series
Comparator: in parallel to the clinical assessment of an acutely decompensating patient
Outcome: The median (IQR) overall NASA TLX task load index | 0 | {"evidence_spans": [{"end": 1795, "start": 1677, "text": "phies. The median (IQR) overall NASA TLX task load index for series was 39 (17 \u2013 58) and for parallel 43 (27 \u2013 52), p\u2009"}], "id": "12100", "pmcid": "5006415", "prompt_id": "12100", "split_group_id": "5006415", "votes": {"0": 2}} |
Objective. Patients with schizophrenia residing at institutions often suffer from negative symptoms, motor, and functional impairments more severe than their noninstitutionalized counterparts. Tai-chi emphasizes body relaxation, alertness, and movement coordination with benefits to balance, focus, and stress relief. ... | Intervention: Tai-chi program and standard residential care
Comparator: standard residential care
Outcome: Motor dexterity and eye hand coordination (CMDT) | 1 | {"evidence_spans": [{"end": 16628, "start": 16245, "text": "pical antipsychotics.\r\n\r\n3.2. Movement Coordination\r\nMotor dexterity and eye hand coordination (CMDT) after attending the Tai-chi class (T2) was not vastly different from baseline (T1). But the waitlist group experienced significant deterioration on 3 of... |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.